---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-053894"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:58:02.655971+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma

## Summary
- Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.
- HSV-1 seropositive patients had median OS 14.2 months vs 7.8 months for seronegative; seroconversion linked to improved survival.
- Treatment well tolerated with no dose-limiting toxicity; increased immune cell infiltration and T-cell repertoire diversity observed.
- Arm C will evaluate up to six injections of CAN-3110, supported by Break Through Cancer foundation.
- Publication in Nature titled 'Clinical trial links oncolytic immunoactivation to survival in glioblastoma'.

## SEC filing metadata
- accession: 0000950170-23-053894
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/0000950170-23-053894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/cadl-20231018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-053894
- JSON: https://secwatch.observer/filing/0000950170-23-053894.json
- Plain text: https://secwatch.observer/filing/0000950170-23-053894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.